IMEP is a chemotherapy regimen that is effective for nasal NK-/T-cell lymphoma. This chemotherapy regimen was also tested in Hodgkin lymphoma as a part of a multidrug alternating scheme COPP/ABV/IMEP. But in that setting it showed no advantage in efficacy and toxicity compared to the use of ABVD or the alternating COPP/ABVD scheme.
Drug regimen Drug Dose Mode Days Ifosfamide 1500 mg/m2 with mesna IV infusion Days 1-3 Methotrexate 30 mg/m2 IV bolus Days 3 and 10 Etoposide 100 mg/m2 IV infusion Days 1-3 Prednisone 120 mg PO qd Days 1-5
References